These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37381977)

  • 1. A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer.
    Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C; Dong Y; Veneris J; Pothuri B
    Future Oncol; 2023 Aug; 19(25):1709-1714. PubMed ID: 37381977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.
    Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
    Future Oncol; 2021 Oct; 17(29):3781-3785. PubMed ID: 34427115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".
    Mirza MR; Chase DM; Slomovitz BM; Christensen RD; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; Coleman RL; Powell MA
    Future Oncol; 2024 Jul; ():1-18. PubMed ID: 38990090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England.
    Goulden S; Heffernan K; Sen Nikitas F; Shukla U; Knott C; Hunger M; Pahwa A; Schade R
    Int J Gynecol Cancer; 2023 Nov; 33(11):1715-1723. PubMed ID: 37620100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
    Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm.
    Goulden S; Shen Q; Coleman RL; Mathews C; Hunger M; Pahwa A; Schade R
    J Health Econ Outcomes Res; 2023; 10(2):53-61. PubMed ID: 37701519
    [No Abstract]   [Full Text] [Related]  

  • 7. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
    Dioun S; Chen L; Melamed A; Gockley A; St Clair CM; Hou JY; Khoury-Collado F; Hur C; Elkin E; Accordino M; Hershman DL; Wright JD
    BJOG; 2023 Jan; 130(2):214-221. PubMed ID: 36330672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world dostarlimab use in advanced/recurrent endometrial cancer in France.
    Rodrigues M; Eberst L; Follana P; Gauthier L; Jacquemin V; Tessier C; El Mouaddin N; Boudier P; Fiteni F; Angeli E; Roche S; Delanoy N; Sabatier R; Flippot R; de la Motte Rouge T
    Bull Cancer; 2023 Oct; 110(10):1041-1050. PubMed ID: 37659907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer.
    Shukla S; Patel H; Chen S; Sun R; Wei L; Chen ZS
    Cancer Pathog Ther; 2024 Jul; 2(3):135-141. PubMed ID: 39027143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
    Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
    JAMA Oncol; 2020 Nov; 6(11):1766-1772. PubMed ID: 33001143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab.
    Kristeleit R; Mathews C; Redondo A; Boklage S; Hanlon J; Im E; Brown J
    Int J Gynecol Cancer; 2022 Aug; 32(10):1250-7. PubMed ID: 35973737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer.
    Mathews C; Lorusso D; Coleman RL; Boklage S; Garside J
    Oncologist; 2022 Dec; 27(12):1058-1066. PubMed ID: 36124638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy.
    Farzeen Z; Khan RRM; Chaudhry AR; Pervaiz M; Saeed Z; Rasheed S; Shehzad B; Adnan A; Summer M
    J Oncol Pharm Pract; 2024 Dec; 30(8):1411-1431. PubMed ID: 39056234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dostarlimab for the treatment of advanced endometrial cancer.
    Redondo A; Gallego A; Mendiola M
    Expert Rev Clin Pharmacol; 2022 Jan; 15(1):1-9. PubMed ID: 35184615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of PD-1 target engagement of dostarlimab and pembrolizumab in advanced solid tumors using ex vivo IL-2 stimulation data.
    Austin D; Melhem M; Gandhi Y; Lu S; Visser S
    CPT Pharmacometrics Syst Pharmacol; 2023 Jan; 12(1):87-94. PubMed ID: 36317409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Integrated Analysis of Dostarlimab Immunogenicity.
    Lu S; Bowsher RR; Clancy A; Rosen A; Zhang M; Yang Y; Koeck K; Gao M; Potocka E; Guo W; Jen KY; Im E; Milton A
    AAPS J; 2021 Jul; 23(5):96. PubMed ID: 34324079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.
    Kumar S; Ghosh S; Sharma G; Wang Z; Kehry MR; Marino MH; Neben TY; Lu S; Luo S; Roberts S; Ramaswamy S; Danaee H; Jenkins D
    MAbs; 2021; 13(1):1954136. PubMed ID: 34313545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dostarlimab (Jemperli) for endometrial cancer.
    Med Lett Drugs Ther; 2023 Apr; 65(1673):e64-e65. PubMed ID: 37020346
    [No Abstract]   [Full Text] [Related]  

  • 19. In brief: A new endometrial cancer indication for dostarlimab (Jemperli).
    Med Lett Drugs Ther; 2023 Aug; 65(1683):e138. PubMed ID: 37651299
    [No Abstract]   [Full Text] [Related]  

  • 20. Dostarlimab: First Approval.
    Markham A
    Drugs; 2021 Jul; 81(10):1213-1219. PubMed ID: 34106455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.